^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Regimen: | VR-CAP (bortezomib + cyclophosphamide + doxorubicin hydrochloride + + Rituxan (rituximab)) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
01/20/2021
Excerpt:
Mantle Cell Lymphoma: INDUCTION THERAPY…Preferred…VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone)
